Compare Neurocrine Biosciences Inc (NBIX) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Public Storage — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Public Storage trades at $294.6 (market cap $55.59B). The key difference: Public Storage is far larger — about 3.5× Neurocrine Biosciences Inc's market cap, and Public Storage pays a 3.97% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PSA | |
|---|---|---|
Market Cap | $15.77B | $55.59B |
Sector | Health | Real Estate |
52-Week High | $185.50 | $330.47 |
52-Week Low | $123.10 | $258.44 |
Enterprise Value | $15.78B | $69.86B |
Dividend Yield | — | 3.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Public Storage (PSA) trades at $301.6, down slightly by 0.14% today, with a bearish technical signal. The stock has consistently beaten earnings expectations in recent quarters, with Q3 2026 results pending. Recent developments include the completion of the Public Storage Canada acquisition and a C$400 million senior notes offering in Canada. Valuation ratios are elevated, with a P/E of 28.82 and P/S of 10.88, while profitability remains strong with a net income margin of 41.8%.
The outlook is mixed: strong fundamentals and dividend payments support the stock, but high valuation and bearish technicals pose risks. Analyst consensus is a 'Hold' with a price target of $334.13, suggesting modest upside. Key risks include execution of recent acquisitions and sensitivity to interest rate changes. Investors should weigh solid earnings performance against premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
